Timothy Nuce, MD
Family Medicine · Kalispell, MTNPI 1376795674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 26.7% of the total. 2025 is the largest year on record at $1,259, more than ten times the $19 reported in 2021. Among family medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$893
- AstraZeneca$684
- Otsuka America Pharmaceutical, Inc.$260
- Boehringer Ingelheim$208
- Neurocrine Biosciences, Inc.$205
- Vanda Pharmaceuticals Inc.$152
- plus $950 from 16 others
What the payments were for
- Food & beverage$3,352100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $893 |
| AstraZeneca | 22 | $684 |
| Otsuka America Pharmaceutical, Inc. | 13 | $260 |
| Boehringer Ingelheim | 10 | $208 |
| Neurocrine Biosciences, Inc. | 9 | $205 |
| Vanda Pharmaceuticals Inc. | 8 | $152 |
| Merck | 7 | $151 |
| Lilly USA, LLC | 8 | $140 |
| Exact Sciences | 5 | $117 |
| Bayer | 5 | $75 |
| Johnson & Johnson | 3 | $58 |
| Novo Nordisk | 4 | $58 |
| Amgen | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Indivior Inc. | 2 | $38 |
| Organon | 3 | $32 |
| GSK | 2 | $32 |
| Pfizer | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$262
- AIRSUPRA$262
- BEVESPI AEROSPHERE$154
- BREZTRI$108
How this compares
$3,352 in reported general payments places this provider in the 95th percentile of 426 family medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 87 | $102,960 |
| OzempicSemaglutide | 104 | $98,312 |
| FarxigaDapagliflozin Propanediol | 66 | $49,788 |
| JardianceEmpagliflozin | 43 | $38,981 |
| EliquisApixaban | 32 | $26,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,284 |
| Xtampza ErOxycodone Myristate | 13 | $20,912 |
| MyrbetriqMirabegron | 28 | $18,140 |
| TrulicityDulaglutide | 16 | $17,126 |
| XareltoRivaroxaban | 17 | $14,388 |
| BelbucaBuprenorphine Hcl | 11 | $9,448 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $7,388 |
| JanuviaSitagliptin Phosphate | 13 | $6,539 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $3,840 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $140 | $120,086103 claims |
| Novo NordiskOzempic | $58 | $98,312104 claims |
| AstraZenecaFarxiga | $684 | $49,78866 claims |
| Boehringer IngelheimJardiance | $208 | $38,98143 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $32 | $27,11339 claims |
| PfizerEliquis | $31 | $26,58532 claims |
| Johnson & JohnsonXarelto | $58 | $14,38817 claims |
| MerckJanuvia | $151 | $6,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 family medicine providers in Montana.
Other family medicine in Kalispell
- John TremperKalispell$951
- Kimberly BlakesleeMissoula$186K
- Kathleen Harder-BrouwerHamilton$28K
- Joey BanksMissoula$21K
- Julie ReilBillings$9K
- Jeanne Pereles OrtizBillings$7K
- Aubrey RemmersMissoula$5K
- Lyle OnstadGreat Falls$5K
- Carey WelshGreat Falls$5K
- Christina HoBillings$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.